PURPOSE: Magnetic resonance imaging-guided linear accelerator systems (MR-linacs) can facilitate the daily adaptation of radiation therapy plans. Here, we report our early clinical experience using a MR-linac for adaptive radiation therapy of gynecologic malignancies. METHODS AND MATERIALS: Treatments were planned with an Elekta Monaco v5.4.01 and delivered by a 1.5 Tesla Elekta Unity MR-linac. The system offers a choice of daily adaptation based on either position (ATP) or shape (ATS) of the tumor and surrounding normal structures. The ATS approach has the option of manually editing the contours of tumors and surrounding normal structures before the plan is adapted. Here, we documented the duration of each treatment fraction; set-up variability (assessed by isocenter shifts in each plan) between fractions; and, for quality assurance, calculated the percentage of plans meeting the γ-criterion of 3%/3-mm distance to agreement. Deformable accumulated dose calculations were used to compare accumulated versus planned dose for patient treated with exclusively ATP fractions. RESULTS: Of the 10 patients treated with 90 fractions on the MR-linac, most received boost doses to recurrence in nodes or isolated tumors. Each treatment fraction lasted a median 32 minutes; fractions were shorter with ATP than with ATS (30 min vs 42 min, P < .0001). The γ criterion for all fraction plans exceeded >90% (median, 99.9%; range, 92.4%-100%; ie, all plans passed quality assurance testing). The average extent of isocenter shift was <0.5 cm in each axis. The accumulated dose to the gross tumor volume was within 5% of the reference plan for all ATP cases. Accumulated doses for lesions in the pelvic periphery were within <1% of the reference plan as opposed to -1.6% to -4.4% for central pelvic tumors. CONCLUSIONS: The MR-linac is a reliable and clinically feasible tool for treating patients with gynecologic cancer.
PURPOSE: Magnetic resonance imaging-guided linear accelerator systems (MR-linacs) can facilitate the daily adaptation of radiation therapy plans. Here, we report our early clinical experience using a MR-linac for adaptive radiation therapy of gynecologic malignancies. METHODS AND MATERIALS: Treatments were planned with an Elekta Monaco v5.4.01 and delivered by a 1.5 Tesla Elekta Unity MR-linac. The system offers a choice of daily adaptation based on either position (ATP) or shape (ATS) of the tumor and surrounding normal structures. The ATS approach has the option of manually editing the contours of tumors and surrounding normal structures before the plan is adapted. Here, we documented the duration of each treatment fraction; set-up variability (assessed by isocenter shifts in each plan) between fractions; and, for quality assurance, calculated the percentage of plans meeting the γ-criterion of 3%/3-mm distance to agreement. Deformable accumulated dose calculations were used to compare accumulated versus planned dose for patient treated with exclusively ATP fractions. RESULTS: Of the 10 patients treated with 90 fractions on the MR-linac, most received boost doses to recurrence in nodes or isolated tumors. Each treatment fraction lasted a median 32 minutes; fractions were shorter with ATP than with ATS (30 min vs 42 min, P < .0001). The γ criterion for all fraction plans exceeded >90% (median, 99.9%; range, 92.4%-100%; ie, all plans passed quality assurance testing). The average extent of isocenter shift was <0.5 cm in each axis. The accumulated dose to the gross tumor volume was within 5% of the reference plan for all ATP cases. Accumulated doses for lesions in the pelvic periphery were within <1% of the reference plan as opposed to -1.6% to -4.4% for central pelvic tumors. CONCLUSIONS: The MR-linac is a reliable and clinically feasible tool for treating patients with gynecologic cancer.
Authors: Peter McCulloch; Douglas G Altman; W Bruce Campbell; David R Flum; Paul Glasziou; John C Marshall; Jon Nicholl; Jeffrey K Aronson; Jeffrey S Barkun; Jane M Blazeby; Isabell C Boutron; W Bruce Campbell; Pierre-Alain Clavien; Jonathan A Cook; Patrick L Ergina; Liane S Feldman; David R Flum; Guy J Maddern; Jon Nicholl; Bournaby C Reeves; Christoph M Seiler; Steven M Strasberg; Jonathan L Meakins; Deborah Ashby; Nick Black; John Bunker; Martin Burton; Marion Campbell; Kalipso Chalkidou; Iain Chalmers; Marc de Leval; Jon Deeks; Patrick L Ergina; Adrian Grant; Muir Gray; Roger Greenhalgh; Milos Jenicek; Sean Kehoe; Richard Lilford; Peter Littlejohns; Yoon Loke; Rajan Madhock; Kim McPherson; Jonathan Meakins; Peter Rothwell; Bill Summerskill; David Taggart; Parris Tekkis; Matthew Thompson; Tom Treasure; Ulrich Trohler; Jan Vandenbroucke Journal: Lancet Date: 2009-09-26 Impact factor: 79.321
Authors: S J Woodings; J J Bluemink; J H W de Vries; Y Niatsetski; B van Veelen; J Schillings; J G M Kok; J W H Wolthaus; S L Hackett; B van Asselen; H M van Zijp; S Pencea; D A Roberts; J J W Lagendijk; B W Raaymakers Journal: Phys Med Biol Date: 2018-04-19 Impact factor: 3.609
Authors: Brigid A McDonald; Sastry Vedam; Jinzhong Yang; Jihong Wang; Pamela Castillo; Belinda Lee; Angela Sobremonte; Sara Ahmed; Yao Ding; Abdallah S R Mohamed; Peter Balter; Neil Hughes; Daniela Thorwarth; Marcel Nachbar; Marielle E P Philippens; Chris H J Terhaard; Daniel Zips; Simon Böke; Musaddiq J Awan; John Christodouleas; Clifton D Fuller Journal: Int J Radiat Oncol Biol Phys Date: 2020-12-16 Impact factor: 7.038
Authors: Christine Haie-Meder; Richard Pötter; Erik Van Limbergen; Edith Briot; Marisol De Brabandere; Johannes Dimopoulos; Isabelle Dumas; Taran Paulsen Hellebust; Christian Kirisits; Stefan Lang; Sabine Muschitz; Juliana Nevinson; An Nulens; Peter Petrow; Natascha Wachter-Gerstner Journal: Radiother Oncol Date: 2005-03 Impact factor: 6.280
Authors: Shin Yun Lim; Alan Tran; Anh Ngoc Kieu Tran; Angela Sobremonte; Clifton D Fuller; Lori Simmons; Jinzhong Yang Journal: Med Dosim Date: 2021-10-28 Impact factor: 1.482
Authors: M P W Intven; S R de Mol van Otterloo; S Mook; P A H Doornaert; E N de Groot-van Breugel; G G Sikkes; M E Willemsen-Bosman; H M van Zijp; R H N Tijssen Journal: Radiother Oncol Date: 2020-09-22 Impact factor: 6.280
Authors: Marcia M T J Bartels; Inez M Verpalen; Cyril J Ferrer; Derk J Slotman; Erik C J Phernambucq; Joost J C Verhoeff; Wietse S C Eppinga; Manon N G J A Braat; Rolf D van den Hoed; Miranda van 't Veer-Ten Kate; Erwin de Boer; Harry R Naber; Ingrid M Nijholt; Lambertus W Bartels; Clemens Bos; Chrit T W Moonen; Martijn F Boomsma; Helena M Verkooijen Journal: Clin Transl Radiat Oncol Date: 2021-01-15